Ability of Lactobacillus plantarum LS/07 to modify intestinal enzymes activity in chronic diseases prevention.
The ability of probiotic strain Lactobacillus plantarum LS/07 to modify the activity of intestinal bacterial enzymes - β-glucuronidase (β-GLUCUR), β-galactosidase (β-GAL), and β-glucosidase (β-GLU) in prevention of chronic diseases - cancer, atherosclerosis and dysbiosis was investigated. The male Sprague-Dawley rats were randomly divided into 12 experimental groups: controls groups - C (control), AT (atherosclerotic), CC (carcinogenic), dysbiotic groups - each group in combination with antibiotics (ATB), probiotics groups - in combinatioan with probiotic (PRO) alone, and each group with combination of antibiotic and probiotic (ATB+PRO). In the control group the β-glucuronidase activity did not change throughout the experiment. High fat diet in atherosclerotic group significantly increased the activity of β-glucuronidase (P<0.001) and β-glucosidase (P<0.01). Azoxymethane application in carcinogenic group significantly increased β-glucuronidase (P<0.01), but reduced β-glucosidase (P<0.01) activity. Daily application of probiotics alone and in combination with antibiotic increased β-galactosidase, of β-glucosidase, and decreased β-glucuronidase activity. In control antibiotic group we observed significant increase in β-glucuronidase (P<0.05) and decreased β-glucosidase (P<0.01) activity which can be caused by the change of microflora in favor of coliform bacteria. These findings indicate the positive effects of probiotic Lactobacillus plantarum LS/07 and suggest its use in disease prevention in human medicine and some animal species.
Institute of Experimental Medicine, Faculty of Medicine, P. J. Šafárik University, Košice, Slovak Republic.
Emília
E
Hijová
Institute of Experimental Medicine, Faculty of Medicine, P. J. Šafárik University, Košice, Slovak Republic.
Jozef
J
Kuzma
Institute of Experimental Medicine, Faculty of Medicine, P. J. Šafárik University, Košice, Slovak Republic.
Ladislav
L
Strojný
Institute of Experimental Medicine, Faculty of Medicine, P. J. Šafárik University, Košice, Slovak Republic.
Alojz
A
Bomba
Institute of Experimental Medicine, Faculty of Medicine, P. J. Šafárik University, Košice, Slovak Republic.
Izabela
I
Bertková
Institute of Experimental Medicine, Faculty of Medicine, P. J. Šafárik University, Košice, Slovak Republic.
Anna
A
Chmelárová
Institute of Experimental Medicine, Faculty of Medicine, P. J. Šafárik University, Košice, Slovak Republic.
Zdena
Z
Hertelyová
Institute of Experimental Medicine, Faculty of Medicine, P. J. Šafárik University, Košice, Slovak Republic.
Veronika
V
Benetinová
Institute of Experimental Medicine, Faculty of Medicine, P. J. Šafárik University, Košice, Slovak Republic.
Jana
J
Štofilová
Institute of Experimental Medicine, Faculty of Medicine, P. J. Šafárik University, Košice, Slovak Republic.
Ľuboš
Ľ
Ambro
D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D050197:Atherosclerosis / Q000628:therapy; D001419:Bacteria / Q000201:enzymology*; D001426:Bacterial Proteins / Q000378:metabolism; D003131:Combined Modality Therapy / Q000379:methods; D064806:Dysbiosis / Q000628:therapy; D005966:Glucuronidase / Q000378:metabolism; D007422:Intestines / Q000382:microbiology*; D048191:Lactiplantibacillus plantarum / Q000502:physiology*; D008297:Male; D009369:Neoplasms / Q000628:therapy; D019936:Probiotics / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley; D001616:beta-Galactosidase / Q000378:metabolism; D001617:beta-Glucosidase / Q000378:metabolism
D000900:Anti-Bacterial Agents; D001426:Bacterial Proteins; D001617:beta-Glucosidase; D001616:beta-Galactosidase; D005966:Glucuronidase
Sprague-Dawley rats; atherosclerosis; bacterial enzyme; cancer; dysbiosis